Back to discover

Protein / target

Histone-lysine N-methyltransferase EZH2

Encoded byEZH2Q15910Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
Small-molecule tractable
Druggability
Approved Drug
2
Research papers

Protein at a glance

Biological role

RNA polymerase II core promoter sequence-specific DNA binding

Strongest disease association

Lymphoma, Large B-Cell, Diffuse

Via encoding gene EZH2 · Literature evidence · score 0.61

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene.

View complete UniProt function annotation

Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene (PubMed:14532106, PubMed:15225548, PubMed:15385962, PubMed:16618801, PubMed:16936726, PubMed:17344414, PubMed:22323599, PubMed:24474760, PubMed:26581166, PubMed:30026490, PubMed:30923826). Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively (PubMed:15231737, PubMed:17210787, PubMed:18285464, PubMed:22323599, PubMed:30923826). Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599, PubMed:30923826). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation (PubMed:19026781). The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems (PubMed:16357870, PubMed:17200670). Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes (PubMed:16179254, PubMed:18086877, PubMed:20935635). EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA (PubMed:23063525). Regulates the circadian clock via histone methylation at the promoter of the circadian genes (PubMed:16717091). Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription (By similarity)

Subcellular location

Nucleus
Domains and Gene Ontology detail (59)

Domains & features

CXCSET

Gene Ontology

  • Cchromatin
  • Cchromatin silencing complex
  • Cchromosome
  • Cchromosome, telomeric region
  • CESC/E(Z) complex
  • Cheterochromatin
  • Cnucleoplasm
  • Cnucleus
  • Cpericentric heterochromatin
  • Cpronucleus
  • Csynapse
  • Fchromatin binding

746 aa · 85 kDa · 5 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Inhibitory neurotransmissionGOCell proliferation & survivalGOCell migrationGONuclear receptor signallingUniProtTranscriptional regulationUniProt · GOMetabolic enzyme activityGO
View supporting evidence

Inhibitory neurotransmission

  • ·synaptic transmission, GABAergic

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Cell migration

  • ·positive regulation of cell migration

Nuclear receptor signalling

  • ·Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that meth…

Transcriptional regulation

  • ·Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that meth…
  • ·RNA polymerase II cis-regulatory region sequence-specific DNA binding
  • ·RNA polymerase II core promoter sequence-specific DNA binding
  • ·transcription corepressor activity

Metabolic enzyme activity

  • ·histone H3 methyltransferase activity
  • ·histone H3K27 methyltransferase activity
  • ·histone H3K27 trimethyltransferase activity
  • ·histone methyltransferase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene EZH2

Gene-level evidence surfaced through the gene EZH2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Lymphoma
0.66Moderately supported

Somatic mutation evidence dominant · Open Targets 0.44

Lymphoma, Follicular
0.65Moderately supported

Clinical evidence dominant · Open Targets 0.52

Lymphoma, Large B-Cell, Diffuse
0.63Moderately supported

Somatic mutation evidence dominant · Open Targets 0.61

Neoplasms
0.63Moderately supported

Clinical evidence dominant · Open Targets 0.43

Melanoma
0.59Moderately supported

Somatic mutation evidence dominant · Open Targets 0.46

View evidence synthesis (5)
LymphomaModerately supported
0.66
agreement 0.560.77
Somatic mutation43%Pathway33%Literature12%Clinical11%

Open Targets aggregate 0.44 · 4 independent evidence families

Lymphoma, FollicularModerately supported
0.65
agreement 0.490.80
Clinical92%Literature8%

Open Targets aggregate 0.52 · 2 independent evidence families

Lymphoma, Large B-Cell, DiffuseModerately supported
0.63
agreement 0.510.75
Somatic mutation65%Literature19%Clinical16%

Open Targets aggregate 0.61 · 3 independent evidence families

NeoplasmsModerately supported
0.63
agreement 0.510.75
Clinical57%Somatic mutation25%Literature19%

Open Targets aggregate 0.43 · 3 independent evidence families

MelanomaModerately supported
0.59
agreement 0.490.70
Somatic mutation37%Pathway31%Literature18%Clinical14%

Open Targets aggregate 0.46 · 4 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Lymphoma, Large B-Cell, Diffuse0.61
Neurodegenerative Diseases0.52
Lymphoma, Follicular0.52
Virus Diseases0.49
Melanoma0.46
Breast Neoplasms0.45
Lymphoma0.44
Leukemia, Myeloid, Acute0.43
Neoplasms0.43

Drug development

3 compounds recorded · 2 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (3)
GSK2816126Phase 1
TAZEMETOSTATApproval
TAZEMETOSTAT HYDROBROMIDEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Duan R · Journal of hematology & oncology · 2020

Recent

Europe PMC papers linked directly to this protein.